Is there a rationale for the continuous infusion of cefepime? A multidisciplinary approach

被引:9
作者
Bernard, E
Breilh, D
Bru, JP
Chiche, D
Dujardin, I
Garraffo, R
Goldstein, F
Lavrard, I
Potel, G
机构
[1] Hop Hotel Dieu, Lab Antibiol, Fac Med, F-44000 Nantes, France
[2] Hop Archet, Nice, France
[3] Hop Haut Leveque, Pessac, France
[4] Ctr Hosp Gen, Annecy, France
[5] Bristol Myers Squibb Co, Paris, France
[6] Hop Louis Pasteur, F-06002 Nice, France
[7] Hop St Joseph, F-75674 Paris, France
关键词
beta-lactamas; cefepime; cephalosporin; continuous infusion; dosage regimen; BETA-LACTAM ANTIBIOTICS; CYSTIC-FIBROSIS PATIENTS; RESISTANT PSEUDOMONAS-AERUGINOSA; KLEBSIELLA-PNEUMONIAE PNEUMONIA; BROAD-SPECTRUM CEPHALOSPORINS; CRITICALLY ILL PATIENTS; ENTEROBACTER-CLOACAE; THERAPEUTIC EFFICACY; INTERMITTENT BOLUS; FIBRIN CLOTS;
D O I
10.1046/j.1469-0691.2003.00587.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This review is the fruit of multidisciplinary discussions concerning the continuous administration of beta-lactams, with a special focus on cefepime. Pooling of the analyses and viewpoints of all members of the group, based on a review of the literature on this subject, has made it possible to test the hypothesis concerning the applicability of this method of administering cefepime. Cefepime is a cephalosporin for injection which exhibits a broader spectrum of activity than that of older, third-generation cephalosporins for injection (cefotaxime, ceftriaxone, ceftazidime). The specific activity of cefepime is based on its more rapid penetration (probably due to its zwitterionic structure, this molecule being both positively and negatively charged) through the outer membrane of Gram-negative bacteria, its greater affinity for penicillin-binding proteins, its weak affinity for beta-lactamases, and its stability versus certain beta-lactamases, particularly derepressed cephalosporinases. The stability of cefepime in various solutions intended for parenteral administration has been studied, and the results obtained demonstrated the good compatibility of cefepime with these different solutions. These results thus permit the administration of cefepime in a continuous infusion over a 24-h period, using two consecutive syringes.
引用
收藏
页码:339 / 348
页数:10
相关论文
共 58 条
[1]   Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration [J].
Allaouchiche, B ;
Breilh, D ;
Jaumain, H ;
Gaillard, B ;
Renard, S ;
Saux, MC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2424-2427
[2]   GENERAL-PRINCIPLES OF ANTIBIOTIC TISSUE PENETRATION [J].
BARZA, M ;
CUCHURAL, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 15 :59-75
[3]   Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections [J].
Benko, AS ;
Cappelletty, DM ;
Kruse, JA ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :691-695
[4]   PHARMACODYNAMICS OF ANTIBIOTICS IN FIBRIN CLOTS [J].
BERGERON, MG ;
ROBERT, J ;
BEAUCHAMP, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 :113-136
[5]  
BERNARD E, 1997, 17 INT M ANT CHEM PA
[6]   RANDOMIZED STUDY OF CARBENICILLIN PLUS CEFAMANDOLE OR TOBRAMYCIN IN THE TREATMENT OF FEBRILE EPISODES IN CANCER-PATIENTS [J].
BODEY, GP ;
KETCHEL, SJ ;
RODRIGUEZ, V .
AMERICAN JOURNAL OF MEDICINE, 1979, 67 (04) :608-616
[7]  
BREILH D, 1996, 16 INT M ANT CHEM PA, P198
[8]   SELECTION FREQUENCY OF RESISTANT VARIANTS BY VARIOUS BETA-LACTAM ANTIBIOTICS IN CLINICAL ENTEROBACTER-CLOACAE ISOLATES [J].
BUSCHER, KH ;
CULLMANN, W ;
DICK, W ;
STIEGLITZ, M .
CHEMOTHERAPY, 1987, 33 (01) :40-51
[9]   A FUNCTIONAL CLASSIFICATION SCHEME FOR BETA-LACTAMASES AND ITS CORRELATION WITH MOLECULAR-STRUCTURE [J].
BUSH, K ;
JACOBY, GA ;
MEDEIROS, AA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) :1211-1233
[10]   PHARMACODYNAMICS OF CEFTAZIDIME ADMINISTERED AS CONTINUOUS-INFUSION OR INTERMITTENT BOLUS ALONE AND IN COMBINATION WITH SINGLE DAILY-DOSE AMIKACIN AGAINST PSEUDOMONAS-AERUGINOSA IN AN IN-VITRO INFECTION MODEL [J].
CAPPELLETTY, DM ;
KANG, SL ;
PALMER, SM ;
RYBAK, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) :1797-1801